EyePoint Pharmaceuticals
Delivering Innovation to the Eye™ NOW HIRING!
Delivering Innovation to the Eye™ NOW HIRING!
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $215.90M | - | 05 Dec 2023 | |
| Post-IPO Debt | $45.00M | 1 | Silicon Valley Bank | 09 Mar 2022 |
| Post-IPO Equity | $115.40M | - | 16 Nov 2021 | |
| Post-IPO Equity | $115.00M | - | 04 Feb 2021 | |
| Post-IPO Equity | $15.70M | 1 | Ocumension Therapeutics | 03 Jan 2021 |
No recent news or press coverage available for EyePoint Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
